PCSK9

Coral reef sea underwater

Biotech

Merck's oral PCSK9 makes waves with 3rd phase 3 win

After 24 weeks of once-daily oral dosing, LDL-C was significantly lower in the enlicitide arm than in the control group.

Nick Paul Taylor Sep 2, 2025 9:35am

heart cardiovascular check up stethescope

AZ's oral PCSK9 inhibitor halves bad cholesterol in phase 2

Mar 31, 2025 12:00pm

Graphic of someone in a boat navigating the rise and fall of different data riding data plots like a wave

Verve halts VERVE-101 enrollment, focuses on 2nd PCSK9 editor

Apr 2, 2024 7:00am

start line beginning road path starting point journey

Merck bets big on oral PCSK9 inhibitor with phase 3 program

Aug 25, 2023 8:35am

germ line gene editing DNA pass down family tree inherit

FDA hands Verve list of demands for lifting gene editing hold

Dec 5, 2022 9:20am

AstraZeneca dumps drug despite hit in phase 2 cholesterol trial

Sep 23, 2022 5:23am